A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults

“…Several fully published, modelled pharmacoeconomic analyses of PCV13 in adults have been conducted in various European countries [46][47][48][49][50][51] and in the USA [52][53][54][55][56][57] ( Table 2). All of the analyses incorporated data from a number of different sources, such as published clinical trials and expert opinion, although none were recent enough to include data from CAPiTA.…”

“…was less costly and less expensive than) the comparator strategy. In addition to the CEAs, a smaller number of budget impact analyses (BIAs) have been conducted with PCV13 in adults, which also compared various vaccination strategies and estimated effects of PCV13 vaccination on net costs and clinical outcomes, but did not consider effects on quality-adjusted life-expectancy or provide ICERs [46,48,49,57].…”

“…A German study showed that replacing PPSV23 with PCV13 would increase the net budget by &€60-152 million over 5 years with equivocal effects on IPD [46], whereas BIAs with 5-year time horizons conducted in Italy [48] and Spain [49] showed that PCV13 reduced costs and pneumococcal disease compared with no vaccination (Table 2). In addition, a BIA with a lifetime horizon conducted in the USA showed that replacing PPSV23 with a single dose of PCV13 in adults aged C50 years would save billions of dollars and reduce pneumococcal disease [57] ( Table 2).…”

Vaccines are different: A systematic review of budget impact analyses of vaccines

“…Two studies (9%) had their vaccine efficacy data source consisting exclusively of economic evaluations held in for- eign countries [17,21]. Studies concerning the PCV13 used adjustments and premises generated by math formulas in order to describe the vaccine's efficacy, which was based on PCV7 and PCV9 clinical trials in children [19,20], and on PPV23 data [13,18,24]. Nine studies (41%) based their analysis on studies from other countriess.…”

“…In order to capture these features, methods to conduct BIA of vaccines might need to encompass a wider range of approaches than those traditionally used for assessing drugs. Therefore, this article assessed how BIAs are currently been conducted, whether there Effects of PCV childhood immunization were not included Jiang [24] (1) PCV13…”